All In Biotech

Drug Trial Radar · NCT01826916

EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema

EDEMA2: An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema

Last checked: Nov 20, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

77

Actual

Start

Nov 1, 2003

Primary completion

Dec 1, 2005

Study completion Jan 1, 2006

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Apr 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EDEMA2 is an open-label, Phase 2 dose-ranging study designed to assess the safety and efficacy of repeated dosing of DX-88 (recombinant plasma kallikrein inhibitor) in Patients with Hereditary Angioedema.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • DX-88 (ecallantide)Drug

    solution for injection 10 mg/mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of attacks treated with successful outcomeTime frame: 24 hours
  2. Proportion of attacks with a partial responseTime frame: 24 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.